Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

The way I interpret the 5/26/16 pr is that "The primary endpoint was was a 2-point reduction in the IGA score at Day 84."

Couple the above quote from the pr with a sentence a few lines below it in the pr, which notes "As previously released, the trial achieved its primary endpoint in patients treated with 200mg of oral Prurisol."

Anyhow, I believe it is clear that in the 2a trial those who were on prurisol benefited more(at a higher rate) than the placebo arm, with the 200mg dose faring better than the 50mg and 100 mg prurisol arms and the 50 & 100mg prurisol arms fared better than the placebo arm.